FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308372101> ?p ?o ?g. }

• W4308372101 endingPage "118" @default.
• W4308372101 startingPage "113" @default.
• W4308372101 abstract "Patients with refractory or relapsed and refractory myeloid malignancies have a poor prognosis. Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning (MAC) in patients with active, chemotherapy-refractory myeloid disease is historically associated with high rates of relapse and nonrelapse mortality (NRM). A MAC regimen combining clofarabine with busulfan (Clo/Bu4) has been reported to exhibit antileukemic activity with acceptable toxicity in patients age ≤70 years. Here we describe the clinical outcomes of a real-world population of patients with active myeloid malignancies undergoing allogeneic HCT with Clo/Bu4 MAC. In a single-center retrospective descriptive analysis, we identified patients who underwent HCT for myeloid malignancies not in remission using Clo/Bu4 MAC between 2012 and 2020. We report event-free survival (EFS) and overall survival (OS), cumulative incidences of relapse and NRM, and the incidence and severity of acute and chronic graft-versus-host disease (GVHD). We identified 69 patients with a median age of 60 years (range, 22 to 70 years). Most patients had relapsed/refractory or primary refractory acute myelogenous leukemia (AML; n = 55) or refractory myelodysplastic syndrome (MDS; n = 12); 1 patient had chronic myelogenous leukemia, and 1 patient had a blastic plasmacytoid dendritic cell neoplasm. Fifty patients (72.5%) had complete remission at day 100 post-transplantation. Two-year EFS and OS were 30% (95% confidence interval [CI], 20% to 44%) and 40% (95% CI, 29% to 54%), respectively. Patients with AML had a 2-year EFS and OS of 28% (95% CI, 18% to 44%) and 38% (95% CI, 27% to 54%), respectively; those with MDS had a 2-year EFS and OS of 47% (95% CI, 25% to 88%) and 56% (95% CI, 33% to 94%), respectively. The cumulative incidence of relapse at 2 years was 39% (95% CI, 27% to 51%) for all patients, including 45% (95% CI, 31% to 58%) in the patients with AML and 18% (95% CI, 2% to 45%) in those with MDS. NRM at 2 years was 31% (95% CI, 20% to 42%), including 27% (95% CI, 15% to 39%) in patients with AML and 35% (95% CI, 10% to 63%) in those with MDS. The total incidence of acute GVHD (aGVHD) of any severity was 80%, and the incidence of grade III-IV aGVHD was 22%. In patients who achieved remission, those who required systemic immunosuppression for aGVHD (58%) had poorer 2-year EFS (29% versus 54%; P = .05) and 2-year OS (39% versus 70%; P = .04) compared to those who did not. The 2-year cumulative incidence of chronic GVHD was 44% (95% CI, 28% to 58%). Clo/Bu4 MAC followed by allogeneic HCT for patients with active myeloid malignancies is an effective transplantation strategy for patients up to age 70, particularly those with advanced MDS. The high incidence of and poor outcomes associated with aGVHD highlight the importance of optimizing preventative strategies." @default.
• W4308372101 created "2022-11-11" @default.
• W4308372101 creator A5002715084 @default.
• W4308372101 creator A5004823514 @default.
• W4308372101 creator A5014838335 @default.
• W4308372101 creator A5023287139 @default.
• W4308372101 creator A5023420856 @default.
• W4308372101 creator A5029801761 @default.
• W4308372101 creator A5037460404 @default.
• W4308372101 creator A5039491957 @default.
• W4308372101 creator A5040440615 @default.
• W4308372101 creator A5041976525 @default.
• W4308372101 creator A5045709974 @default.
• W4308372101 creator A5047973111 @default.
• W4308372101 creator A5051165777 @default.
• W4308372101 creator A5068492086 @default.
• W4308372101 creator A5071923722 @default.
• W4308372101 creator A5072029350 @default.
• W4308372101 creator A5076648040 @default.
• W4308372101 creator A5089409657 @default.
• W4308372101 creator A5090231849 @default.
• W4308372101 creator A5091612581 @default.
• W4308372101 date "2023-02-01" @default.
• W4308372101 modified "2023-09-26" @default.
• W4308372101 title "Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies" @default.
• W4308372101 cites W1812948889 @default.
• W4308372101 cites W1861829463 @default.
• W4308372101 cites W1971100781 @default.
• W4308372101 cites W1974632374 @default.
• W4308372101 cites W1976750551 @default.
• W4308372101 cites W1987350756 @default.
• W4308372101 cites W1992090010 @default.
• W4308372101 cites W1995360806 @default.
• W4308372101 cites W2001895625 @default.
• W4308372101 cites W2014383528 @default.
• W4308372101 cites W2016937505 @default.
• W4308372101 cites W2022015347 @default.
• W4308372101 cites W2030012469 @default.
• W4308372101 cites W2038981426 @default.
• W4308372101 cites W2046464784 @default.
• W4308372101 cites W2048306988 @default.
• W4308372101 cites W2068021983 @default.
• W4308372101 cites W2079801336 @default.
• W4308372101 cites W2093298135 @default.
• W4308372101 cites W2103628120 @default.
• W4308372101 cites W2106947293 @default.
• W4308372101 cites W2143034151 @default.
• W4308372101 cites W2143342566 @default.
• W4308372101 cites W2153588399 @default.
• W4308372101 cites W2163863527 @default.
• W4308372101 cites W2207795634 @default.
• W4308372101 cites W2466681359 @default.
• W4308372101 cites W2492745064 @default.
• W4308372101 cites W2507996775 @default.
• W4308372101 cites W2537710036 @default.
• W4308372101 cites W2547033890 @default.
• W4308372101 cites W2552133019 @default.
• W4308372101 cites W2559537906 @default.
• W4308372101 cites W2575545223 @default.
• W4308372101 cites W2593885173 @default.
• W4308372101 cites W2610625257 @default.
• W4308372101 cites W3010820032 @default.
• W4308372101 cites W3133628729 @default.
• W4308372101 cites W4293241248 @default.
• W4308372101 cites W70277491 @default.
• W4308372101 doi "https://doi.org/10.1016/j.jtct.2022.10.027" @default.
• W4308372101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36336258" @default.
• W4308372101 hasPublicationYear "2023" @default.
• W4308372101 type Work @default.
• W4308372101 citedByCount "1" @default.
• W4308372101 countsByYear W43083721012023 @default.
• W4308372101 crossrefType "journal-article" @default.
• W4308372101 hasAuthorship W4308372101A5002715084 @default.
• W4308372101 hasAuthorship W4308372101A5004823514 @default.
• W4308372101 hasAuthorship W4308372101A5014838335 @default.
• W4308372101 hasAuthorship W4308372101A5023287139 @default.
• W4308372101 hasAuthorship W4308372101A5023420856 @default.
• W4308372101 hasAuthorship W4308372101A5029801761 @default.
• W4308372101 hasAuthorship W4308372101A5037460404 @default.
• W4308372101 hasAuthorship W4308372101A5039491957 @default.
• W4308372101 hasAuthorship W4308372101A5040440615 @default.
• W4308372101 hasAuthorship W4308372101A5041976525 @default.
• W4308372101 hasAuthorship W4308372101A5045709974 @default.
• W4308372101 hasAuthorship W4308372101A5047973111 @default.
• W4308372101 hasAuthorship W4308372101A5051165777 @default.
• W4308372101 hasAuthorship W4308372101A5068492086 @default.
• W4308372101 hasAuthorship W4308372101A5071923722 @default.
• W4308372101 hasAuthorship W4308372101A5072029350 @default.
• W4308372101 hasAuthorship W4308372101A5076648040 @default.
• W4308372101 hasAuthorship W4308372101A5089409657 @default.
• W4308372101 hasAuthorship W4308372101A5090231849 @default.
• W4308372101 hasAuthorship W4308372101A5091612581 @default.
• W4308372101 hasConcept C121332964 @default.
• W4308372101 hasConcept C126322002 @default.
• W4308372101 hasConcept C141071460 @default.
• W4308372101 hasConcept C142424586 @default.
• W4308372101 hasConcept C143998085 @default.
• W4308372101 hasConcept C2777198975 @default.

• next